ArticleFrontiers in immunology2022
Alveolar macrophages in early stage COPD show functional deviations with properties of impaired immune activation.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 46 citations in OpenAlex.
- Defective alveolar regeneration in emphysema: identifying dysfunctional cellular crosstalk and novel therapeutic opportunities for tissue repair.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Fueling the fire: metabolic dysfunction and senescence as drivers of lung aging and disease.Physiological reviews · 2026Review
- Prognostic comparison of ablation and laser excision in a population-based cohort of stage III-IV pulmonary malignant tumors.Journal of cardiothoracic surgery · 2026Article
- Endothelial cell senescence shapes T cell activity in late-stage of chronic obstructive pulmonary disease.Cell death discovery · 2026Article
- Discovery of Marine-Inspired Guanidine-Based PDE4 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.Marine drugs · 2026Article
- Emerging role of the immunoproteasome as a druggable target in lung inflammatory diseases.Respiratory research · 2026Review
- Inhaled Targeted Nano-Drug Delivery Systems for COPD: Precision Solutions to Clinical Barriers.International journal of nanomedicine · 2026Review
- Ampicillin-Loaded Fenugreek-Derived Exosomes Treat COPD via Anti-Inflammatory, Antibacterial and Anti-Fibrotic Effects.International journal of nanomedicine · 2026Article
- Identification and Validation of a Two-Gene NK Cell-Related Risk Model for COPD: Integration of Single-Cell and Bulk RNA-Seq Analysis.International journal of chronic obstructive pulmonary disease · 2026Article
- Immune-metabolic positive feedback model in COPD: cross-mechanisms and potential intervention strategies.Frontiers in cell and developmental biology · 2026Review
- Cholesterol-mediated inflammation activation in alveolar macrophages.BMC biology · 2025Article
- ANT1 Deficiency Impairs Macrophage Metabolism and Migration, Protecting Against Emphysema in Chronic Obstructive Pulmonary Disease.American journal of respiratory cell and molecular biology · 2025Article
- Exosomal MicroRNA let-7 Modulates Lipid Metabolism and Inflammation in Foamy Macrophages of Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2025Article
- Single-cell transcriptomic analysis of blood and bronchoalveolar lavage fluid in progressive fibrosing interstitial lung diseases.Scientific reports · 2025Article
- Dissecting the role of gut microbiota heterogeneity in the onset of chronic lung diseases.AMB Express · 2025Article
- Extracellular vesicular delivery of ceramides from pulmonary macrophages to endothelial cells facilitates chronic obstructive pulmonary disease.Cell communication and signaling : CCS · 2025Article
- SIRT1 regulates cigarette smoke extract‑induced alveolar macrophage polarization and inflammation by inhibiting the TRAF6/NLRP3 signaling pathway.Molecular medicine reports · 2025Article
- Associations of Serum Legumain with Severity and Prognosis Among Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients.International journal of chronic obstructive pulmonary disease · 2025Article
- Developmental immune network of airway lymphocytes and innate immune cells in patients with stable COPD.Frontiers in immunology · 2025Article
- Advances on the Role of Lung Macrophages in the Pathogenesis of Chronic Obstructive Pulmonary Disease in the Era of Single-Cell Genomics.International journal of medical sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors at 12 institutions in 3 countries.
Kevin BaßlerGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Wataru FujiiGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Theodore S KapellosGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Erika DudkinComputational Life Sciences, Life & Medical Sciences (LIMES) Institute, University of Bonn, Neuherberg, Germany.
Nico ReuschGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Ari HorneGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Benedikt ReizComma Soft AG, Bonn, Germany.
Malte D LueckenHelmholtz Zentrum München - German Research Center for Environmental Health, Institute of Computational Biology, Neuherberg, Germany.
Collins Osei-SarpongImmunogenomics & Neurodegeneration, German Center for Neurodegenerative Diseases and the University of Bonn, Bonn, Germany.
Stefanie Warnat-HerresthalGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Lorenzo BonaguroGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Jonas Schulte-SchreppingGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Allon WagnerDepartment of electrical engineering and computer science, University of California, Berkeley, CA, United States.
Patrick GüntherPRECISE Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn, Bonn, Germany.
Carmen PizarroDepartment of Internal Medicine II, University Hospital Bonn, Section of Pneumology, Bonn, Germany.
Tina SchreiberDepartment of Internal Medicine II, University Hospital Bonn, Section of Pneumology, Bonn, Germany.
Rainer KnollGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Lisa HolstenGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Charlotte KrögerGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Elena De DomenicoPRECISE Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn, Bonn, Germany.
Matthias BeckerPRECISE Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn, Bonn, Germany.
Kristian HändlerPRECISE Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn, Bonn, Germany.
Christian T WohnhaasComputational Biology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Florian BaumgartnerComma Soft AG, Bonn, Germany.
Meike KöhlerComma Soft AG, Bonn, Germany.
Heidi TheisPRECISE Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn, Bonn, Germany.
Michael KrautPRECISE Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn, Bonn, Germany.
Marc H WadsworthInstitute for Medical Engineering & Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States.
Travis K HughesInstitute of Structural Biology, University Hospital, University of Bonn, Bonn, Germany.
Humberto J FerreiraPRECISE Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn, Bonn, Germany.
Emily HinkleyPRECISE Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn, Bonn, Germany.
Ines H KaltheunerInstitute of Structural Biology, University Hospital, University of Bonn, Bonn, Germany.
Matthias GeyerBiochemistry & Cell Biology of Lipids, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Christoph ThieleUniversity Clinics for Radiology, University Hospital Bonn, Bonn, Germany.
Alex K ShalekInstitute for Medical Engineering & Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States.
Andreas FeißtUniversity Clinics for Radiology, University Hospital Bonn, Bonn, Germany.
Daniel ThomasUniversity Clinics for Radiology, University Hospital Bonn, Bonn, Germany.
Henning DicktenComma Soft AG, Bonn, Germany.
Marc BeyerImmunogenomics & Neurodegeneration, German Center for Neurodegenerative Diseases and the University of Bonn, Bonn, Germany.
Patrick BaumTranslational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Nir YosefDepartment of electrical engineering and computer science, University of California, Berkeley, CA, United States.
Anna C AschenbrennerPrevention, Aging & Systems Immunology, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany.
Thomas UlasGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Jan HasenauerComputational Life Sciences, Life & Medical Sciences (LIMES) Institute, University of Bonn, Neuherberg, Germany.
Fabian J TheisHelmholtz Zentrum München - German Research Center for Environmental Health, Institute of Computational Biology, Neuherberg, Germany.
Dirk SkowaschDepartment of Internal Medicine II, University Hospital Bonn, Section of Pneumology, Bonn, Germany.
Joachim L SchultzeGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
University of Bonn · DEUniversity Hospital Bonn · DEEpigenomics (Germany) · DEGerman Center for Neurodegenerative Diseases · DEBoehringer Ingelheim (Germany) · DEHelmholtz Zentrum München · DEBroad Institute · USMassachusetts Institute of Technology · USRadboud University Nijmegen · NLRagon Institute of MGH, MIT and Harvard · USTechnical University of Munich · DEUniversity of California, Berkeley · US
Funding
Tool and Technology Development CoreU19MH114821 · NIMH · COLD SPRING HARBOR LABORATORY · PI ARLOTTA, PAOLA, HUANG, Z JOSH · 2017 to 2021
$64.5MQuantitative and functional characterization of therapeutic resistance in cancerU54CA217377 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SHALEK, ALEX K · 2017 to 2021
$10.2MAn integrated multiplexed genomic assay for low input clinical samples1U24AI118672 · NIAID · BROAD INSTITUTE, INC. · PI SHALEK, ALEX K · 2015 to 2019
$2.0MNCI NIH HHS U54 CA217377NIAID NIH HHS U24 AI118672NIMH NIH HHS U19 MH114821
Abstract
Despite its high prevalence, the cellular and molecular mechanisms of chronic obstructive pulmonary disease (COPD) are far from being understood. Here, we determine disease-related changes in cellular and molecular compositions within the alveolar space and peripheral blood of a cohort of COPD patients and controls. Myeloid cells were the largest cellular compartment in the alveolar space with invading monocytes and proliferating macrophages elevated in COPD. Modeling cell-to-cell communication, signaling pathway usage, and transcription factor binding predicts TGF-β1 to be a major upstream regulator of transcriptional changes in alveolar macrophages of COPD patients. Functionally, macrophages in COPD showed reduced antigen presentation capacity, accumulation of cholesteryl ester, reduced cellular chemotaxis, and mitochondrial dysfunction, reminiscent of impaired immune activation.
Indexed as
Macrophages, AlveolarPulmonary Disease, Chronic ObstructiveChemotaxisHumansMacrophagesMonocytesbloodbronchoalveolar lavagechronic obstructive pulmonary diseaseimpaired immune activationmacrophagemonocyteTGF-β1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.